Company
Celldex Therapeutics
Celldex Therapeutics has 25 drugs tracked on RxWires: 2 in Phase 3, 7 in Phase 2, 6 in Phase 1/2, 10 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Rindopepimut (CDX-110) with GM-CSF | Phase 3 | Glioblastoma |
| barzolvolimab | Phase 3 | Chronic Spontaneous Urticaria |
| CG53135-05, velafermin | Phase 2 | Stomatitis |
| glembatumumab vedotin | Phase 2 | Melanoma |
| Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Phase 2 | Glioblastoma |
| CDX-011 | Phase 2 | Breast Cancer |
| velafermin | Phase 2 | Oral Mucositis |
| CDX-110 with GM-CSF | Phase 2 | Malignant Glioma |
| CDX-1307 Vaccine Regimen | Phase 2 | Bladder Cancer |
| Pembrolizumab | Phase 1/2 | Non-Hodgkin's Lymphoma |
| FLT3 Ligand (CDX-301) | Phase 1/2 | Non Small Cell Lung Cancer |
| 6MHP | Phase 1/2 | Melanoma |
| CR011-vcMMAE | Phase 1/2 | Breast Cancer |
| Combination of varlilumab and nivolumab | Phase 1/2 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Trametinib daily Until PD | Phase 1/2 | Melanoma |
| Combination of Varlilumab and Atezolizumab | Phase 1 | Carcinoma, Renal Cell |
| CDX-622 | Phase 1 | Mild to Moderate Asthma |
| KTN3379 | Phase 1 | Squamous Cell Carcinoma of the Head and Neck |
| odetiglucan | Phase 1 | Metastatic Pancreatic Adenocarcinoma |
| CDX1127 | Phase 1 | Prostatic Neoplasms |
| CDX-0159 | Phase 1 | Healthy Subjects |
| CDX-1127 | Phase 1 | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma |
| CDX-1140 | Phase 1 | Melanoma |
| CDX-301 | Phase 1 | Healthy |
| CDX-585 | Phase 1 | Non-small Cell Lung Cancer |
Latest
- celldex therapeutics filed 8-K
- celldex therapeutics filed 8-K
- celldex therapeutics filed 8-K
- celldex therapeutics filed 8-K
- celldex therapeutics filed 8-K
Follow Celldex Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.